Regulatory Context for Women's Health

Federal statutes, agency rules, and state-level codes collectively shape how women's health services are delivered, covered, and enforced across the United States. This page maps the major regulatory instruments that govern clinical care, insurance access, pharmaceutical approvals, and privacy protections specific to women's health. Understanding how these frameworks interact is essential for evaluating coverage disputes, consent requirements, and clinical compliance obligations.

How rules propagate

Regulatory authority over women's health flows from at least three distinct levels: federal statute, federal agency rulemaking, and state law. Congress passes enabling legislation — such as the Public Health Service Act or the Affordable Care Act (ACA) — that delegates specific rulemaking authority to federal agencies. Those agencies, including the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Centers for Medicare & Medicaid Services (CMS), then issue binding regulations published in the Code of Federal Regulations (CFR).

State governments retain concurrent authority over licensure of healthcare providers, scope-of-practice definitions, and insurance market regulation. When federal and state rules conflict, the Supremacy Clause of the U.S. Constitution generally controls the outcome, though states may impose standards stricter than federal minimums in areas such as informed consent or Medicaid eligibility. The result is a layered system: a provider practicing in California faces different informed-consent obligations than the same provider in Texas, even under identical federal baseline requirements.

For women's health specifically, HHS's Office on Women's Health (OWH) — established under the Public Health Service Act at 42 U.S.C. § 300 et seq. — coordinates cross-agency policy and research priorities, although OWH does not itself issue enforceable regulations.

Enforcement and review paths

Enforcement authority is distributed across multiple agencies depending on the subject matter.

FDA enforces drug and device safety under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.), including approvals for contraceptives, hormone therapies, and diagnostic devices relevant to breast health and screening. Civil monetary penalties, product recalls, and Warning Letters are primary enforcement tools.
CMS oversees Medicare and Medicaid compliance, including coverage mandates for preventive services under ACA Section 2713, which requires zero cost-sharing for preventive care rated "A" or "B" by the U.S. Preventive Services Task Force (USPSTF).
Office for Civil Rights (OCR) within HHS enforces the Health Insurance Portability and Accountability Act (HIPAA) Privacy and Security Rules (45 CFR Parts 160 and 164). Penalties under HIPAA range from $100 to $50,000 per violation, with an annual cap of $1.9 million per violation category (HHS HIPAA Enforcement).
Equal Employment Opportunity Commission (EEOC) enforces the Pregnancy Discrimination Act (PDA) and the Pregnant Workers Fairness Act (PWFA), which took effect June 27, 2023 (EEOC PWFA Overview).
State attorneys general and insurance commissioners handle complaints related to coverage denials and network adequacy.

Judicial review of agency rules proceeds under the Administrative Procedure Act (APA, 5 U.S.C. § 551 et seq.), where challengers may argue rules are arbitrary, capricious, or contrary to statute. The 2022 Supreme Court decision in Dobbs v. Jackson Women's Health Organization (597 U.S. 215) eliminated the federal constitutional right to abortion and returned legislative authority to individual states, fundamentally altering the enforcement landscape for reproductive health regulation.

Primary regulatory instruments

The table below contrasts the four most consequential regulatory instruments for women's health:

Instrument	Primary Authority	Scope
ACA Preventive Services Mandate	42 U.S.C. § 300gg-13 / CMS	Contraceptives, mammograms, cervical cancer screening, gestational diabetes testing
HIPAA Privacy Rule	45 CFR Part 164	Protection of reproductive health information, minimum necessary standards
Title X Family Planning Program	42 U.S.C. § 300	Federally funded contraception, STI testing, and related services for low-income patients
FDA Drug Approval Pathways	21 CFR Parts 312–314	New Drug Applications (NDAs) and Priority Review for obstetric and gynecologic drugs

The ACA contraceptive mandate, as interpreted by HHS through the HRSA Women's Preventive Services Guidelines, requires coverage of all FDA-approved contraceptive methods without cost-sharing for non-grandfathered group health plans. Religious and moral exemptions were upheld by the Supreme Court in Little Sisters of the Poor Saints Peter and Paul Home v. Pennsylvania (591 U.S. ___, 2020). Information relevant to contraception options for women depends substantially on how these exemptions apply in a given employment context.

Compliance obligations

Entities operating in women's health — hospitals, outpatient clinics, pharmaceutical manufacturers, and insurance issuers — carry distinct compliance obligations:

Providers must satisfy HIPAA's minimum necessary standard for reproductive health records, maintain state-specific informed consent documentation (particularly for pregnancy health and prenatal care), and comply with CMS Conditions of Participation (42 CFR Part 482) to receive Medicare or Medicaid reimbursement.
Insurers must comply with ACA market reforms including the prohibition on sex-based underwriting (45 CFR § 147.104) and the Section 1557 nondiscrimination provisions administered by OCR.
Pharmaceutical manufacturers must meet FDA postmarket surveillance requirements under 21 CFR Part 314.81, including filing Field Alert Reports within 3 calendar days for distributed products with safety concerns.
Employers with 15 or more employees are subject to PDA and PWFA accommodation obligations enforceable through the EEOC.

Health disparities in women's health are also subject to regulatory attention through Section 1557 of the ACA, which prohibits discrimination on the basis of sex, race, color, national origin, age, and disability in federally funded health programs. The index of topics on this site reflects the breadth of clinical areas where these regulatory frameworks apply simultaneously.

For a full overview of coverage rights and insurance navigation, see women's health insurance and coverage.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)